KRAS and neoplasm: Achieves precise targeting of KRAS G12D‐mutated tumors through mutation‐specific RNA interference and local sustained‐release delivery, inhibiting tumor progression from multiple dimensions including proliferation, apoptosis, angiogenesis, and the immune microenvironment